| 1 | 1 | | 89R9017 AB-D |
|---|
| 2 | 2 | | By: VanDeaver H.B. No. 4783 |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | |
|---|
| 6 | 6 | | |
|---|
| 7 | 7 | | A BILL TO BE ENTITLED |
|---|
| 8 | 8 | | AN ACT |
|---|
| 9 | 9 | | relating to a report on governmental opioid antagonist programs to |
|---|
| 10 | 10 | | reverse and prevent opioid overdoses. |
|---|
| 11 | 11 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 12 | 12 | | SECTION 1. Subchapter B, Chapter 461A, Health and Safety |
|---|
| 13 | 13 | | Code, is amended by adding Section 461A.060 to read as follows: |
|---|
| 14 | 14 | | Sec. 461A.060. BIENNIAL REPORT ON OPIOID ANTAGONIST |
|---|
| 15 | 15 | | PROGRAMS FOR OPIOID OVERDOSE REVERSAL AND PREVENTION. (a) In this |
|---|
| 16 | 16 | | section, "opioid antagonist" has the meaning assigned by Section |
|---|
| 17 | 17 | | 483.101. |
|---|
| 18 | 18 | | (b) Not later than October 1 of each even-numbered year, the |
|---|
| 19 | 19 | | commission shall: |
|---|
| 20 | 20 | | (1) prepare a report evaluating the distribution of |
|---|
| 21 | 21 | | opioid antagonists in this state to reverse and prevent opioid |
|---|
| 22 | 22 | | overdoses; and |
|---|
| 23 | 23 | | (2) submit the report to the governor, the lieutenant |
|---|
| 24 | 24 | | governor, and the speaker of the house of representatives. |
|---|
| 25 | 25 | | (c) The report described by Subsection (b) must: |
|---|
| 26 | 26 | | (1) include a needs assessment for the opioid |
|---|
| 27 | 27 | | antagonist program established under Section 461A.059; |
|---|
| 28 | 28 | | (2) establish a statewide saturation goal for opioid |
|---|
| 29 | 29 | | antagonists and include: |
|---|
| 30 | 30 | | (A) a description of the data sources and |
|---|
| 31 | 31 | | methodology used to estimate insufficiencies in the current supply |
|---|
| 32 | 32 | | of opioid antagonists; and |
|---|
| 33 | 33 | | (B) a communications plan to address opioid |
|---|
| 34 | 34 | | overdoses in areas of this state at higher risk for increased |
|---|
| 35 | 35 | | numbers of overdoses; |
|---|
| 36 | 36 | | (3) include a description of all state and federal |
|---|
| 37 | 37 | | money appropriated to the opioid antagonist program established |
|---|
| 38 | 38 | | under Section 461A.059; |
|---|
| 39 | 39 | | (4) establish opioid antagonist distribution |
|---|
| 40 | 40 | | strategies for this state; |
|---|
| 41 | 41 | | (5) list and describe all available state and |
|---|
| 42 | 42 | | federally funded purchase and distribution programs for opioid |
|---|
| 43 | 43 | | antagonists; and |
|---|
| 44 | 44 | | (6) recommend improvements for addressing opioid |
|---|
| 45 | 45 | | overdoses among high-risk populations, including school-aged |
|---|
| 46 | 46 | | children, pregnant and postpartum women, and individuals residing |
|---|
| 47 | 47 | | in rural areas of this state. |
|---|
| 48 | 48 | | (d) In preparing the report under this section, the |
|---|
| 49 | 49 | | commission shall coordinate and consult with each state agency, |
|---|
| 50 | 50 | | institution of higher education, and political subdivision of this |
|---|
| 51 | 51 | | state that receives funding or other resources under Section |
|---|
| 52 | 52 | | 461A.059 for the distribution of opioid antagonists. |
|---|
| 53 | 53 | | SECTION 2. This Act takes effect September 1, 2025. |
|---|